Hormone replacement therapy: current controversies
نویسندگان
چکیده
منابع مشابه
Hormone Therapy for Prostate Cancer: Exploring Current Controversies
65.[13] Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3): an open randomised phase III trial. Lancet 2009;373: 301–8.[14] D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289–95.<...
متن کاملHormone replacement therapy.
HRT is indicated for the treatment of moderate ▪ to severe vasomotor and urogenital symptoms associated with menopause. HRT is not recommended for primary prevention of ▪ disease because of increased risk of other adverse events. The use of HRT increases the risk of stroke, venous ▪ thromboembolism (VTE) and gall bladder disease and combined oestrogen progestogen therapy is also associated with...
متن کاملPostmenopausal hormone replacement therapy.
Several comprehensive accounts of postmenopausal hormone replacement treatment have been published in the United Kingdom in the past year`so in this review we concentrate on areas which, while often controversial, are of concern to the practising physician. We discuss the effects of postmenopausal hormone replacement therapy on the risks of developing coronary heart disease, osteoporosis, and c...
متن کاملSubcutaneous hormone replacement therapy.
It is estimated that 75% of women are in an acute estrogen deficiency state within a few years after the onset of the menopause. Every woman inevitably reaches this phase except for a fortunate few who have some source of endogenous estrogens available to them. We believe it would be prudent to offer hormone replacement therapy to every woman with symptoms of the menopause, and to those in whom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Endocrinology
سال: 2003
ISSN: 0300-0664
DOI: 10.1046/j.1365-2265.2003.01774.x